Diabetes News

CHICAGO — Middle-aged and older adults who consumed greater amounts of ultraprocessed foods, or UPFs, had an approximately 10% increased risk for death over a median follow-up period of 23 years, according to a study presented at NUTRITION.

Exposure to workplace sexual harassment was associated with elevated risk for developing CVD and type 2 diabetes, according to a study published in European Journal of Preventive Cardiology.

A 5:2 intermittent fasting diet combined with meal replacement resulted in greater weight loss and better glycemic control compared with antidiabetic medications in patients with early-stage type 2 diabetes, data from the EARLY study showed.

In patients with obesity-driven heart failure with preserved ejection fraction, semaglutide 2.4 mg was associated with more improvement in NYHA functional class compared with placebo, according to new data from the STEP-HFpEF trials.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

ORLANDO — Semaglutide use was associated with significant reductions in worsening of kidney disease, cardiovascular events and all-cause death vs. placebo for adults with type 2 diabetes regardless of concomitant use of SGLT2 inhibitors.

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.

ORLANDO — Among adults with obesity-related heart failure with preserved ejection fraction, women taking semaglutide lost significantly more weight than men, but greater weight loss did not result in extra health benefits for women vs. men.

ORLANDO — The generic lipid-lowering drug fenofibrate was associated with a significant reduction in progression of diabetic retinopathy and maculopathy, researchers reported.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.